MRNAModerna, Inc.

Moderna Third Quarter 2026 Conference Call - MODERNA INC

Good day and thank you for standing by. Welcome to Moderna's third quarter 2026 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answ ...

Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction

The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.  ...

Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates

Reports third quarter revenue of $1.3 billion, GAAP net income of $0.2 billion and GAAP diluted EPS of $0.38Increases 2026 expected revenue growth to 15%-25%, exceeding the previous expectation of up to 10% ...

Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Moderna reports Q3 earnings Friday, with analysts expecting a $1.25 loss per share and $890M revenue; shares fell 6.6% after vaccine approvals. ...

Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines

Canada becomes the first country to authorize both Moderna's mRNA seasonal influenza vaccine, mFLUSIVA®, and combination influenza and COVID-19 vaccine, mCOFLU® CAMBRIDGE, MA / ACCESS Newswire / November 5, ...

Moderna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 Study

WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 clinical results CAMBRIDGE, MA / ACCESS Newswire / November 4, 2026 / Moderna, Inc. ...

Moderna Announces Oral Presentation of mRNA-2808 Clinical Data at 2026 American Society of Hematology Annual Meeting

Initial Phase 1/2 data highlight the potential of Moderna's multiplexed mRNA approach in relapsed or refractory multiple myeloma CAMBRIDGE, MA / ACCESS Newswire / November 4, 2026 / Moderna, Inc. ...

Merck One of Top Large-Cap Biopharma Picks-Analyst

Merck beats Q3 estimates on oncology strength and raised guidance, while Guggenheim eyes pipeline progress ahead of Keytruda patent loss. ...

This M&T Bank Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Analysts downgraded M&T Bank, Bank of Hawaii, HubSpot, Abbott and Moderna; Bank of Hawaii cut its target, while HubSpot’s rose. ...

William Blair Downgrades Moderna to Market Perform

William Blair analyst Myles Minter downgrades Moderna from Outperform to Market Perform. ...

Piper Sandler Reiterates Overweight on Moderna, Raises Price Target to $230

Piper Sandler analyst Edward Tenthoff reiterates Moderna with a Overweight and raises the price target from $167 to $230. ...

Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Cancer treatment is moving into a new phase, and immuno-oncology is right at the center of it. Instead of relying only on drugs that attack tumors directly, researchers are ...

A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets

AUSTIN, Texas, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - An mRNA-based cancer therapy designed around each patient’s own tumor has delivered positive Phase 3 results. On October 22, Merck and ...

Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall

Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma treatment. ...

Did You Lose Money on Moderna, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 23.07% Share Price Decline

Investigation comes after a October 22, 2026 report concerning Moderna, Inc.; shareholders who suffered losses may have claims to recover them Investors who suffered losses on Moderna, Inc. ("Moderna" or the ...

Moderna Named a Top Employer by Science for Twelfth Consecutive Year

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2026 / Moderna, Inc. today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2026 Top ...

Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium

Intismeran plus KEYTRUDA significantly reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45–0.75]; two-sided p<0.001) compared to KEYTRUDA alone for patients with completely resected stage IIB-IV ...

Moderna shares plunge after leak of partial cancer vaccine data

Moderna's stock fell even though the full data, released later Thursday, appeared positive based on Wall Street expectations ahead of the release. ...

TD Cowen Maintains Hold on Moderna, Raises Price Target to $90

TD Cowen analyst Tyler Van Buren maintains Moderna with a Hold and raises the price target from $40 to $90. ...

OpenAI acquires startup Orchestra Bio⁠ to beef up its biotech business

Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $137

Goldman Sachs analyst Salveen Richter maintains Moderna with a Neutral and raises the price target from $120 to $137. ...

Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make

His comments come after Merck officially opened its new 120,000-square-foot research facility in the Greater Philadelphia area. ...

AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

News Provided by Biotech Insider on behalf of MindWalk Holdings Corp. BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For most of the past decade, the promise of AI in drug discovery was ...

Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026

CAMBRIDGE, MA / ACCESS Newswire / October 13, 2026 / Moderna, Inc. , today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, November 6, 2026 to report its third ...

Morgan Stanley Maintains Equal-Weight on Moderna, Raises Price Target to $95

Morgan Stanley analyst Terence Flynn maintains Moderna with a Equal-Weight and raises the price target from $89 to $95. ...